WATERTOWN, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) — EyePoint Prescribed drugs, Inc. (NASDAQ: NASDAQ:), an organization dedicated to growing and commercializing therapeutics to assist enhance the lives of sufferers with severe retinal illnesses, right this moment introduced that the Firm granted non-statutory inventory choices to new workers as inducement awards outdoors the Firm’s 2023 Lengthy-Time period Incentive Plan in accordance with NASDAQ Itemizing Rule 5635(c)(4).
The Firm granted inventory choices to buy as much as an combination of 54,600 shares of EyePoint Prescribed drugs frequent inventory to 6 new workers. The inventory choices had been granted on December 13, 2024. The grants had been accredited by the Compensation Committee and made as an inducement materials to every worker coming into into employment with EyePoint Prescribed drugs in accordance with NASDAQ Itemizing Rule 5635(c)(4). The choice awards have an train value of $7.46 per share, the closing value of EyePoint Prescribed drugs’ frequent inventory on December 13, 2024. The choices have a ten-year time period and vest over 4 years, with 25% of the unique variety of shares vesting on the primary anniversary of the relevant worker’s date of grant and the rest vesting in equal month-to-month installments over the next three years. Vesting of the choices is topic to the worker’s continued service with EyePoint Prescribed drugs via the relevant vesting dates.
About EyePoint Prescribed drugs
EyePoint Prescribed drugs (Nasdaq: EYPT) is a clinical-stage biopharmaceutical firm dedicated to growing and commercializing progressive therapeutics to assist enhance the lives of sufferers with severe retinal illnesses. The Firm’s pipeline leverages its proprietary bioerodible Durasert E™ expertise for sustained intraocular drug supply. The Firm’s lead product candidate, DURAVYU™ (f/ok/a EYP-1901), is an investigational sustained supply remedy for VEGF-mediated retinal illnesses combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. DURAVYU is presently in Section 3 international, pivotal scientific trials as a sustained supply remedy for moist AMD (NASDAQ:), the main explanation for imaginative and prescient loss amongst individuals 50 years of age and older in the US, and in a Section 2 scientific trial in DME. EyePoint expects full topline knowledge from the Section 2 scientific trial in DME in Q1 2025 and topline knowledge from each Section 3 pivotal trials in moist AMD in 2026.
Pipeline packages embrace EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E™ to probably enhance outcomes in severe retinal illnesses. The confirmed Durasert ® drug supply expertise has been safely administered to 1000’s of affected person eyes throughout 4 U.S. FDA accredited merchandise. EyePoint Prescribed drugs is headquartered in Watertown, Massachusetts.
Vorolanib is licensed to EyePoint completely by Equinox Sciences, a Betta Prescribed drugs affiliate, for the localized remedy of all ophthalmic illnesses outdoors of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA because the proprietary identify for EYP-1901. DURAVYU is an investigational product; it has not been accredited by the FDA. FDA approval and the timeline for potential approval is unsure.
For EyePoint Prescribed drugs:
Buyers:
Christina Tartaglia
Precision AQ (previously Stern (AS:) IR)
Direct: 212-698-8700
christina.tartaglia@precisionaq.com
Media Contact:
Amy Phillips
Inexperienced Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
Supply: EyePoint Prescribed drugs, Inc.
